Success Metrics

Clinical Success Rate
57.1%

Based on 8 completed trials

Completion Rate
57%(8/14)
Active Trials
4(16%)
Results Posted
38%(3 trials)
Terminated
6(24%)

Phase Distribution

Ph not_applicable
10
40%
Ph phase_1
4
16%
Ph phase_2
2
8%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
4(25.0%)
Phase 2Efficacy & side effects
2(12.5%)
N/ANon-phased studies
10(62.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

53.3%

8 of 15 finished

Non-Completion Rate

46.7%

7 ended early

Currently Active

4

trials recruiting

Total Trials

25

all time

Status Distribution
Active(4)
Completed(8)
Terminated(7)
Other(6)

Detailed Status

Completed8
Terminated6
unknown6
Recruiting2
Active, not recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
4
Success Rate
57.1%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (25.0%)
Phase 22 (12.5%)
N/A10 (62.5%)

Trials by Status

completed832%
withdrawn14%
terminated624%
recruiting28%
active_not_recruiting28%
unknown624%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT04214249Phase 2

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Active Not Recruiting
NCT04652960Phase 1

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Active Not Recruiting
NCT03699995Not Applicable

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Terminated
NCT03874052Phase 1

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
NCT02958462Not Applicable

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Recruiting
NCT07414797Not Applicable

Discomfort Following Oral Biopsy Comparing Laser and Punch Biopsy

Completed
NCT05393713Phase 1

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Terminated
NCT04541017Phase 1

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Terminated
NCT03785834

The Effect of Histopathologic Analysis and Tissue Cultures on Inpatient Management of Cellulitis and Pseudocellulitis

Completed
NCT06205615Phase 2

Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

Completed
NCT00955578

Genetic Identification (ID) of Segmental Dysplastic Nevi

Withdrawn
NCT03271580

Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing

Terminated
NCT05902455

Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis

Unknown
NCT05247710

Differential Mobility Spectrometry (DMS) Based Skin Tumor Analysis

Unknown
NCT04896346

Scarring in Stratagraft-treated vs. Autograft-treated Burn Wounds: a Clinical and Histological Investigation

Unknown
NCT03443362

Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.

Unknown
NCT01813149Not Applicable

Mechanism and Treatment of Sympathetically Maintained Pain

Terminated
NCT04620395Not Applicable

Percutaneous Punch Biopsy for Diagnosis of Septic and Aseptic Prosthetic Joint Failure

Unknown
NCT03048721Not Applicable

Skin Tape Harvesting for Transcriptomics Analysis

Completed
NCT02623101Not Applicable

Reflectance Confocal Microscopy in Basal Cell Carcinoma

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
25